StockData
Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc. (PBYI) stock

PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)

Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –

Puma Biotechnology total assets

Total assets on the balance sheet at the end of each period.

Puma Biotechnology's total assets was $192.74M at Jun 30, 2026. For fiscal 2025 it was $216.30M, up 1.4% from the year before. Over ten years it grew -1.0% a year on average. The highest annual figure on record is $259.12M in fiscal 2018.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$216.30M+1.4%
FY2024Dec 31, 2024$213.33M-7.5%
FY2023Dec 31, 2023$230.53M+3.8%
FY2022Dec 31, 2022$222.06M-2.0%
FY2021Dec 31, 2021$226.59M-7.2%
FY2020Dec 31, 2020$244.22M+4.0%
FY2019Dec 31, 2019$234.91M-9.3%
FY2018Dec 31, 2018$259.12M+56.5%
FY2017Dec 31, 2017$165.53M-34.5%
FY2016Dec 31, 2016$252.79M+5.4%
FY2015Dec 31, 2015$239.84M+47.4%
FY2014Dec 31, 2014$162.76M+55.9%
FY2013Dec 31, 2013$104.37M-31.2%
FY2012Dec 31, 2012$151.70M+173.8%
FY2011Dec 31, 2011$55.40M+11990809.1%
FY2010Dec 31, 2010$462–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$192.74M-1.1%
Q1 FY2026Mar 31, 2026$192.70M-1.8%
Q4 FY2025Dec 31, 2025$216.30M+1.4%
Q3 FY2025Sep 30, 2025$202.86M-8.1%
Q2 FY2025Jun 30, 2025$194.92M-4.9%
Q1 FY2025Mar 31, 2025$196.18M-8.4%
Q4 FY2024Dec 31, 2024$213.33M-7.5%
Q3 FY2024Sep 30, 2024$220.72M+8.4%
Q2 FY2024Jun 30, 2024$205.00M+2.2%
Q1 FY2024Mar 31, 2024$214.15M+9.1%
Q4 FY2023Dec 31, 2023$230.53M+3.8%
Q3 FY2023Sep 30, 2023$203.61M+2.4%
Q2 FY2023Jun 30, 2023$200.49M+3.5%
Q1 FY2023Mar 31, 2023$196.26M-2.2%
Q4 FY2022Dec 31, 2022$222.06M-2.0%
Q3 FY2022Sep 30, 2022$198.77M-12.2%
Q2 FY2022Jun 30, 2022$193.65M-25.5%
Q1 FY2022Mar 31, 2022$200.69M-22.4%
Q4 FY2021Dec 31, 2021$226.59M-7.2%
Q3 FY2021Sep 30, 2021$226.29M-13.5%
Q2 FY2021Jun 30, 2021$260.00M-1.4%
Q1 FY2021Mar 31, 2021$258.66M+14.7%
Q4 FY2020Dec 31, 2020$244.22M+4.0%
Q3 FY2020Sep 30, 2020$261.70M+12.8%
Q2 FY2020Jun 30, 2020$263.81M+10.0%
Q1 FY2020Mar 31, 2020$225.53M-31.9%
Q4 FY2019Dec 31, 2019$234.91M-9.3%
Q3 FY2019Sep 30, 2019$232.04M+0.6%
Q2 FY2019Jun 30, 2019$239.86M+5.4%
Q1 FY2019Mar 31, 2019$331.36M+95.3%
Q4 FY2018Dec 31, 2018$259.12M+56.5%
Q3 FY2018Sep 30, 2018$230.72M+26.9%
Q2 FY2018Jun 30, 2018$227.62M+31.7%
Q1 FY2018Mar 31, 2018$169.64M-21.7%
Q4 FY2017Dec 31, 2017$165.53M-34.5%
Q3 FY2017Sep 30, 2017$181.86M+35.7%
Q2 FY2017Jun 30, 2017$172.82M–
Q1 FY2017Mar 31, 2017$216.62M–
Q4 FY2016Dec 31, 2016$252.79M–
Q3 FY2016Sep 30, 2016$134.03M–

More Puma Biotechnology figures

See a number that looks wrong?